HACKENSACK, N.J.--(BUSINESS WIRE)--Amorcyte, Inc. (Amorcyte), a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, announced today that its phase I clinical trial is now open in two new clinical sites and the data safety monitoring board has approved the trial going forward to the second stage using, as per the approved protocol, an increased number of stem cells.
